Vienna - Delayed Quote EUR

Galapagos NV (GLPG.VI)

22.18

-0.08

(-0.36%)

At close: January 31 at 3:30:34 PM GMT+1

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Galapagos (GLPG) said Wednesday that it plans to split into two entities, with a new company, or Spi

PREMIUM
MT Newswires 23 days ago

GILD

GLPG.AS
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncolog

GlobeNewswire 24 days ago

GLPG

GLPGF
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In ad

GlobeNewswire 24 days ago

GLPG

GLPGF
Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

Key Insights Galapagos' significant retail investors ownership suggests that the key decisions are influenced by...

Simply Wall St. last month

GLPG

GLPGF
ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

Clinical Trials Arena last month

GLPG.AS
$Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma$

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy.These data reinforce the potential of Galapagos’ decentralized cell therapy manufacturing platf

GlobeNewswire last month

GLPG

GLPGF
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our c

GlobeNewswire 2 months ago

GLPG

GLPGF
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos ( AMS:GLPG ) Third Quarter 2024 Results Key Financial Results Revenue: €59.8m (down 50% from 3Q 2023). Net...

Simply Wall St. 2 months ago

GLPG

GLPGF
Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...

Galapagos NV (GLPG) reports a robust cash reserve and significant advancements in its R&D pipeline, while navigating increased R&D costs and competitive market pressures.

GuruFocus.com 2 months ago

GLPG.AS
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance o

GlobeNewswire 3 months ago

GLPG

GLPGF
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos’ ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to

GlobeNewswire 3 months ago

GLPG

GLPGF
Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 30 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 26 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified us that EcoR1 Capital LLC holds 7,094,049 of Galapagos’ voting rights, consisting of 6,939,043 ordinary shares and 155,006 American Depository Re

GlobeNewswire 3 months ago

GLPG

GLPGF
Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 August 2024 from FMR LLC, who notified that it holds 2,687,116 of Galapagos’ voting rights, consisting of 2,686,016 ordinary shares and 1,100 equivalent financial instruments. FMR LLC controls investment funds Fidelity Management & Resear

GlobeNewswire 4 months ago

GLPG

GLPGF
Even after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five years

This week we saw the Galapagos NV ( AMS:GLPG ) share price climb by 13%. But will that heal all the wounds inflicted...

Simply Wall St. 4 months ago

GLPG

GLPGF
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.

Zacks 5 months ago

REGN

LXRX

RYTM
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

Zacks 5 months ago

GLPG.AS

ARCT

FULC
$Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma$

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product cand

GlobeNewswire 5 months ago

GLPG

GLPGF
ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload

By Michael Kim NASDAQ:ADAP READ THE FULL ADAP RESEARCH REPORT Pre-market open on 8/12/24, Adaptimmune (NASDAQ:ADAP) reported 2Q24 earnings results. ADAP reported net profit of $69.5 million for 2Q24, or $0.04 per diluted ordinary share compared to a net loss of $21.4 million, or ($0.02) per ordinary share for 2Q23. Relative to our model, the EPS beat was largely a function of more favorable

Zacks Small Cap Research 5 months ago

ADAP

GLPG.AS
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, today announced an expansion to its strategic collaboration and licensing agreement with Galapagos NV (Euronext: GLPG) (NASDAQ: GLPG). This new collaboration builds upon the partnership initiated in January 2024, focusing on the discovery of a highly selective oral SMARCA2 small molecule proteolysis targeting chimera (PROTAC).

PR Newswire 5 months ago

GLPG

GLPGF
Galapagos reports half-year 2024 financial results and provides second quarter business update

Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs.Submitted IND application to FDA for our Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 in R/R NHL.Submitted CTA to EMA for our Phase 2 study of GLPG5201 in R/R CLL with or without RT.IND filing for our Phase 1/2 EUPLAGIA-1 study of CD19 CAR-T candidat

GlobeNewswire 5 months ago

GLPG

GLPGF

Performance Overview

Return	GLPG.VI	AEX-Index
YTD	-15.60%	+5.75%
1-Year	-37.47%	+12.34%
3-Year	-62.00%	+23.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Galapagos NV (GLPG.VI)

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities

Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%

ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024

Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)

Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth

Galapagos receives transparency notification from EcoR1 Capital

Galapagos receives transparency notification from FMR LLC

Even after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five years

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma

ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload

BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology

Galapagos reports half-year 2024 financial results and provides second quarter business update

Performance Overview